|
US3227725A
(en)
|
1962-04-17 |
1966-01-04 |
Union Carbide Corp |
Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
|
|
TW201311B
(enExample)
|
1991-06-17 |
1993-03-01 |
Hoffmann La Roche |
|
|
CA2143246C
(en)
|
1994-03-16 |
2000-08-22 |
Thierry Godel |
Imidazodiazepines
|
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
BR0208637A
(pt)
|
2001-04-02 |
2004-12-07 |
Wyeth Corp |
Pd-1, um receptor para b7-4, e usos dos mesmos
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
GB0204159D0
(en)
|
2002-02-22 |
2002-04-10 |
British Biotech Pharm |
Metalloproteinase inhibitors
|
|
US7595048B2
(en)
|
2002-07-03 |
2009-09-29 |
Ono Pharmaceutical Co., Ltd. |
Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
|
|
BR0316880A
(pt)
|
2002-12-23 |
2005-10-25 |
Wyeth Corp |
Anticorpos contra pd-1 e usos dos mesmos
|
|
US7569578B2
(en)
|
2003-12-05 |
2009-08-04 |
Bristol-Meyers Squibb Company |
Heterocyclic anti-migraine agents
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
|
JP5065908B2
(ja)
|
2004-12-24 |
2012-11-07 |
プロシディオン・リミテッド |
Ｇタンパク質結合受容体作動薬
|
|
EP2439273B1
(en)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
WO2006133216A2
(en)
|
2005-06-06 |
2006-12-14 |
Smithkline Beecham Corporation |
4-substituted arylamine derivatives and their use in pharmaceutical compositions
|
|
WO2007075749A2
(en)
|
2005-12-20 |
2007-07-05 |
Merck & Co., Inc. |
Niacin receptor agonists, compositions containing such compounds and methods of treatment
|
|
CN101484433A
(zh)
|
2006-02-15 |
2009-07-15 |
艾博特公司 |
新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
|
|
US20080021026A1
(en)
|
2006-07-20 |
2008-01-24 |
Mehmet Kahraman |
Benzothiophene inhibitors of rho kinase
|
|
AU2007300542B2
(en)
*
|
2006-09-25 |
2012-05-17 |
Ptc Therapeutics, Inc. |
Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
CN101842095B
(zh)
|
2007-07-02 |
2015-06-24 |
于明 |
肿瘤治疗的配方,方法和靶目标
|
|
US7868001B2
(en)
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
|
AU2009217356B2
(en)
|
2008-02-22 |
2012-05-03 |
Irm Llc |
Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors
|
|
WO2010033701A2
(en)
|
2008-09-19 |
2010-03-25 |
Genzyme Corporation |
Inhibitors of sphingosine kinase 1
|
|
WO2010051447A1
(en)
|
2008-10-30 |
2010-05-06 |
Elixir Pharmaceuticals, Inc. |
Sulfonamide containing compounds and uses thereof
|
|
US8217149B2
(en)
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
LT3279215T
(lt)
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Tiksliniai surišantys agentai prieš b7-h1
|
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
|
WO2011137587A1
(en)
|
2010-05-06 |
2011-11-10 |
Hutchison Medipharma Limited |
Cytokine inhibitors
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012129564A2
(en)
|
2011-03-24 |
2012-09-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Proteasome chymotrypsin-like inhibition using pi-1833 analogs
|
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
TWI547493B
(zh)
|
2011-09-27 |
2016-09-01 |
諾華公司 |
作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮
|
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
|
JP2015512910A
(ja)
|
2012-03-29 |
2015-04-30 |
オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
ヒトｐｄ１のｂｃループに由来する免疫調節性環状化合物
|
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳－法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
EP2943487B1
(en)
|
2013-01-09 |
2016-11-16 |
Gilead Sciences, Inc. |
5-membered heteroaryls and their use as antiviral agents
|
|
WO2014141104A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
WO2014147586A1
(en)
|
2013-03-22 |
2014-09-25 |
Novartis Ag |
1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
|
|
ES2675027T3
(es)
|
2013-09-06 |
2018-07-05 |
Aurigene Discovery Technologies Limited |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
|
SG11201601679TA
(en)
*
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
|
PT3702373T
(pt)
|
2013-09-13 |
2022-09-27 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
|
|
GB2516515B8
(en)
|
2013-12-04 |
2016-10-05 |
Intelligent Growth Solutions Ltd |
Automated arrangement to grow plants under lighting in a vertical tower
|
|
US10174012B2
(en)
*
|
2014-11-04 |
2019-01-08 |
The University Of Kansas |
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
|
|
SG11201706902SA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
JP2018507885A
(ja)
|
2015-03-10 |
2018-03-22 |
オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
|
|
CA3220902A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
GB201517217D0
(en)
|
2015-09-29 |
2015-11-11 |
Astex Therapeutics Ltd And Cancer Res Technology Ltd |
Pharmaceutical compounds
|
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
|
WO2018047143A1
(en)
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Vista signaling pathway inhibitory compounds useful as immunomodulators
|
|
WO2018051254A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
|
KR20190067235A
(ko)
|
2016-10-20 |
2019-06-14 |
오리진 디스커버리 테크놀로지스 리미티드 |
Vista 및 pd-1 경로의 이중 억제제
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
BR112020006669A2
(pt)
|
2017-10-11 |
2020-09-24 |
Aurigene Discovery Technologies Limited |
formas cristalinas de 1,2,4-oxadiazol 3-substituído
|
|
MY206121A
(en)
|
2017-11-03 |
2024-11-29 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of tim-3 and pd-1 pathways
|
|
KR20200084333A
(ko)
|
2017-11-06 |
2020-07-10 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절을 위한 병행 요법
|